TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ANTIGEN-SPECIFIC DELETION OF T EFFECTOR CELLS
Publication
EP3871691A1
Kind: A1
Mar 18, 2026
Applicants
Cartesian Therapeutics, Inc.
Inventors
FRASER, Christopher, KISHIMOTO, Takashi Kei, MALDONADO, Roberto
Abstract
Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion).
IPC Classifications
A61K 39/38 20060101AFI20210705BHEP
A61K 47/30 20060101ALI20210705BHEP
A61K 9/127 20060101ALI20210705BHEP
A61K 31/445 20060101ALI20210705BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR